Currently Viewing:
Newsroom
Currently Reading
NCCN Releases Patient Guidelines for Neuroendocrine Tumors
October 10, 2018 – Samantha DiGrande
Some Metro Areas Facing Shortages of Oncologists in Coming Years, Report Says
October 09, 2018 – Allison Inserro
Does Transcriptional Loss of HLA Cause Immunotherapy Resistance?
October 08, 2018 – David Bai
Adherence to NCCN Breast Cancer Guidelines Improves Outcomes
October 06, 2018 – Samantha DiGrande
Second Opinions Beneficial for Patients With Breast Cancer
October 05, 2018 – Samantha DiGrande
Preventing Antimicrobial Complications, Ensuring Stewardship in Cancer Care
October 04, 2018 – Allison Inserro
FDA Approves Once-Weekly Dose of Kyprolis for R/R Multiple Myeloma
October 03, 2018 – Laura Joszt
People Living With HIV Have Higher Risk of First and Second Primary Cancer Incidence
October 01, 2018 – Jaime Rosenberg
FDA Approves NGS-Based Test That Detects Very Low Levels of Cancer Cells in ALL or MM
October 01, 2018 – Laura Joszt

NCCN Releases Patient Guidelines for Neuroendocrine Tumors

Samantha DiGrande
This week, the National Comprehensive Cancer Network (NCCN) published new guidelines for patients centered around neuroendocrine tumors. 
This week, the National Comprehensive Cancer Network (NCCN) published a new set of guidelines for patients centered around neuroendocrine tumors (NET). 

NET can occur in many different parts of the body, varies in symptom presentation, and can require individualized and oftentimes complicated treatment approaches. These updated guidelines offer the latest information in order to assist patients and caregivers in making knowledgeable, shared medical decisions with the help of their provider. 

“Neuroendocrine tumors are complicated and the treatment paths are varied because the disease presents and behaves different in each patient. The NCCN Patient Guidelines offer a common ground of understanding so patients and providers can work as a team to achieve the best possible care,” said Cindy Lovelace, patient and co-founder of The Healing NET Foundation in a statement.

The information provided in the guidelines is based on evidence and expert consensus in clinical practice guidelines created by NCCN’s multidisciplinary panels from 27 leading academic cancer centers throughout the United States. The guidelines cover all aspects of NET, including tests used to diagnose the tumors, an overview of the different treatments offered, and specific treatment guides depending on where the tumors occur in the body.

Formatted specifically for patients, the guidelines and treatment recommendations are presented in user-friendly terms and include illustrations and a glossary to make the information easily digestible. 

“It really takes a multidisciplinary team to treat these tumors. Everybody plays a different role in the care of NETs, including endocrinologists, medical oncologists, surgical oncologists, radiation oncologists, and sometimes nuclear medicine radiologists,” said Whitney Goldner, MD, Fred and Pamela Buffett Cancer Center. “These guidelines help prepare patients for the group of people who will comprise their treatment team, and ensure they understand the need for specific testing and therapies for their tumor.”

Related Articles

ASCO and NCCN Release Guidelines on Managing Immunotherapy-Related Toxicities
NCCN Report on CAR T-Cell Therapy, Recommendations for Future Use
Research at NANETS Cites Value of Genetic Testing in Neuroendocrine Tumors
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up